Pharma BD Deal Intelligence
Valeant Pharmaceuticals (now Bausch Health) acquired AB Sanitas, a Lithuanian specialty/branded-generics maker with a Central and Eastern European footprint, for ~EUR314 million (~$442M) in cash, taking ~87.2% of shares; the deal expanded Valeant's emerging-markets branded-generics platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bausch Health / Sanitas (this deal) | 2011 | $442M | 48 |
| Bausch Health / DURECT Corporation | 2025 | $413M | — |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
← Browse all deals · How we score deals
More: 2011 deals